Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 8, 2013, Pages 620-630

  Zhang, Xiaoping ^a   Chen, Ya Chi ^a   Fettner, Scott ^a   Rowell, Lucy ^b   Gott, Tatiana ^a   Grimsey, Paul ^b   Unsworth, Adam ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Actemra; Interleukin 6; Monoclonal antibody; Pharmacodynamics; Pharmacokinetics; Rheumatoid arthritis; Soluble interleukin 6 receptor; Subcutaneous administration; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6 RECEPTOR; TOCILIZUMAB;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEUTROPHIL COUNT; OPEN STUDY; PARALLEL DESIGN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-6; MALE; MIDDLE AGED;

EID: 84883159838     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201904     Document Type: Article

References (17)

1. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005; 5: 1731-1740. Cross- Ref PubMed
2. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008; 67: 1516-1523. CrossRef PubMed
3. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez- Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008; 58: 2968-2980. CrossRef PubMed
4. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the doubleblind treatment phase of a randomized placebocontrolled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011; 63: 609-621. CrossRef PubMed
5. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos- Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators. Effect of interleukin- 6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371: 987-997. Cross- Ref PubMed
6. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy vs. methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010; 69: 88-96. CrossRef PubMed
7. Genentech, Inc. Actemra® (tocilizumab injection, for intravenous infusion). South San Francisco, CA: Genentech, Inc.; 2012.
8. Roche Registration Limited. RoActemra® (tocilizumab) Summary of product characteristics. Welwyn Garden City, UK; Roche Registration Limited; 2011.
9. Chugai Pharmaceutical Co. Ltd. Product overview of Actemra. Chugai Pharmaceutical Co., Ltd. http://www.chugai-pharm.co.jp/html/meeting/ pdf/080522eShimizu.pdf. Accessed October 1, 2012.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315-324. CrossRef PubMed
11. Zhang X, Peck R. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis. Expert Rev Clin Pharmacol. 2011; 4: 539-558. CrossRef PubMed
12. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009; 35: 745-757. CrossRef PubMed
13. Criteria CT. (CTC), version 3. Cancer Therapy Evaluation Program, 2006.
14. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010; 50: 754-766. CrossRef PubMed
15. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006; 54: 2817-2829. CrossRef PubMed
16. Levi M, Grange S, Frey N. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. J Clin Pharmacol. 2012. In press. PubMed
17. Georgy A, Zhang X, Anzures-Cabrera J, Foley- Comer A. A clinical study to assess the pharmacokinetics and pharmacodynamics of tocilizumab after single-dose administration by subcutaneous and intravenous routes to healthy subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, March 17-20, 2010, Atlanta, Georgia.